Clinical trials: Opioid Agonist Treatment, open to volunteers
Gastrectomy, Postoperative Analgesia
Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Totally Laparoscopic Radical Distal Gastrectomy
Anruikefen is a peripherally highly selective kappa receptor agonist that does not easily cross the blood-brain barrier, resulting in a low incidence of central adverse reactions such as respiratory depression, sedation, and…
- Trial name
- NCT07330063
- Testing
- Anruikefen (Intravenous Bolus), Anruikefen (Intravenous Infusion)
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Opioid Use Disorder, Opioid Abuse and Addiction
GLP-1R Agonist Treatment for Opioid Use Disorder
The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment.
- Conditions
- Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders
- Trial name
- NCT06548490
- Testing
- Semaglutide Pen Injector
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Milton S. Hershey Medical Center
HIV-1-infection, Opioid Use Disorder
Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)
The goal of this clinical trial is to determine the efficacy of Dolutegravir/Lamivudine (DTG/3TC), or "Dovato", in virally-suppressed (HIV-1 RNA < 200 copies/mL) individuals receiving opioid agonist therapy such as methadone…
- Trial name
- NCT06580873
- Testing
- DOVATO
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Saskatchewan Health Authority - Regina Area
Suicidal Ideation, Major Depressive Episode
Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode
This study aims at investigating if adjunctive buprenorphine at low dose to treatment as usual is effective in reducing severe suicidal ideas in major depressive episode, and at determining the most effective dose.
- Trial name
- BUPRIS (NCT03646058)
- Testing
- Buprenorphine
- Where
- 9 sites in France
- Volunteers
- 180 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Opioid Use Disorder, Methadone
Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy
This pilot study will evaluate the feasibility and safety of using 1:1 tetrahydrocannabinol (THC):Cannabidiol (CBD) cannabis oil as an adjunct therapy to methadone-based Opioid Agonist Therapy (OAT) for individuals with opioid…
- Conditions
- Opioid Use Disorder, Methadone, Cannabis, Fentanyl
- Trial name
- THC-MMT (NCT05985850)
- Testing
- Aurora 1:1 Drops (Indica)
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- BC Centre on Substance Use
Opioid Use Disorder
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
This study aims to improve retention in buprenorphine treatment, a medication used for opioid use disorder, through the use of a smartphone-delivered recovery support intervention.
- Trial name
- SARA RCT (NCT06732596)
- Testing
- Embodied conversational agent (ECA), Technical support, Additional ECA messages
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Boston Medical Center
Opioid-use Disorder
Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments
This is a multi-centre, open-label RCT at four Emergency Departments (EDs) in British Columbia and Alberta. The purpose of the current study is to compare the effectiveness of buprenorphine/naloxone microdosing and standard…
- Trial name
- NCT04893525
- Testing
- Buprenorphine/naloxone
- Where
- 6 sites in Canada
- Volunteers
- 658 people
- Sponsor
- University of British Columbia
Opioid Use Disorder
Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial
The goal of this clinical study is to evaluate a new treatment approach called symptom inhibited naloxone induction (SINI) for people with opioid use disorder.
- Trial name
- NCT07439549
- Testing
- Naloxone Hydrochloride 0.4 MG/ML, Buprenorphine hydrochloride and naloxone hydrochloride dihydrate sublingual tablet (2 mg/0.5 mg and 8 mg/2 mg), Buprenorphine extended-release injection (300 mg/1.5 mL)
- Where
- 2 sites in Canada
- Volunteers
- 12 people
- Sponsor
- Pouya Azar
Opioid Use Disorder
Methadone Rapid Restart
The usual treatment for opioid use disorder (OUD) is opioid agonist therapy (OAT) with either methadone or buprenorphine. These treatments are well-established, reduce the risk of fatal overdoses, and are considered the standard…
- Trial name
- NCT07546396
- Testing
- Methadone
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Pouya Azar
HIV - Human Immunodeficiency Virus
HIV Prevention With PrEP Among People on Opioid Replacement Therapy
The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta…
- Trial name
- OAT-PrEP (NCT07160075)
- Testing
- Simultaneous administration of OAT and oral PrEP at existing pharmacy-based programs
- Where
- 6 sites in Canada
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Cara Spence
Healthy Volunteers
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Intravenous Doses of NH302 Injection in Healthy Participants
This is a first-in-human study of NH302 injection in healthy participants. The study will test single intravenous doses of NH302 to evaluate its safety and tolerability, how the body processes NH302, and its effects on selected…
- Trial name
- NCT07892469
- Testing
- NH302 injection
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- The Third Xiangya Hospital of Central South University
Alcohol Use Disorder, Opioid Use Disorder
Better Experiences in Substance Treatment: A Brief Alcohol-focused Intervention Tailored for Patients in Opioid Agonist Treatment
This study will help determine the feasibility and acceptability of a brief opioid-informed alcohol intervention in patients receiving prescribed buprenorphine for opioid use who are currently drinking alcohol.
- Conditions
- Alcohol Use Disorder, Opioid Use Disorder, Alcohol Use, Opioid Use
- Trial name
- Project BEST (NCT07342504)
- Testing
- Brief opioid-informed alcohol treatment
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Notre Dame
Cocaine Use Disorder
Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder
In The Netherlands, each year, about 15 thousand people come into treatment because of problems with cocaine use. There is no approved medication for treatment of cocaine addiction and the psychosocial treatment patients receive…
- Trial name
- NCT05529927
- Testing
- Sustained-release Dexamphetamine
- Where
- Netherlands
- Volunteers
- 204 people
- Sponsor
- Parnassia Addiction Research Centre